Heron Therapeutics (HRTX) Change in Acquisitions & Divestments (2016 - 2026)

Heron Therapeutics (HRTX) has 11 years of Change in Acquisitions & Divestments data on file, last reported at $12.6 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 50.12% year-over-year to $12.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.4 million (down 50.38% YoY) and the FY2025 annual result came in at $67.0 million, down 45.73% from the prior year.
• Change in Acquisitions & Divestments advanced to $12.6 million in Q1 2026, from $7.1 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $51.0 million in Q1 2023 to a low of $7.1 million in Q4 2025.
• A 5-year average of $26.7 million and a median of $25.2 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2024 — Change in Acquisitions & Divestments jumped 122.56% — and 2025, when it sank 70.87%.
• Tracing HRTX's Change in Acquisitions & Divestments over 5 years: stood at $21.0 million in 2022, then decreased by 29.76% to $14.8 million in 2023, then surged by 65.23% to $24.4 million in 2024, then slumped by 70.87% to $7.1 million in 2025, then jumped by 77.34% to $12.6 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $12.6 million (Q1 2026), $7.1 million (Q4 2025), and $18.0 million (Q3 2025), per Business Quant data.